Deep in our cells, a wide range of processes are occurring constantly. These cellular processes rely on enzymes to act as catalysts and set off a series of molecular interactions. There are still many ...

The future of federally funded research at Harvard Medical School — supported by taxpayers and done in service to humanity — remains uncertain. Learn more. One of the most enduring goals in ...

Jan 20 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and Canada-based privately held Aspect Biosystems said on Tuesday they have struck a partnership to develop cell-based ...

University of New South Wales (UNSW) engineers have improved the performance of solar cells made from antimony chalcogenide (Sb2(S,Se)3), reaching a champion power conversion efficiency of 11.02% in ...

Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, today announced the promotion of three accomplished executives to strengthen its leadership team and ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy. California-based Orca filed for FDA ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Small Cap Annovis Bio Inc. (NYSE: ANVS) stock is trading higher on Monday, with a session volume of 12.29 million compared to the average volume of 615.12 thousand as per data from Benzinga Pro. A ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...

A Stanford-led team has replaced toxic pre-transplant chemotherapy with a targeted antibody, allowing children with Fanconi anemia to receive stem cell transplants safely. The antibody, briquilimab, ...